U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry UNKNOWN
Molecular Formula C17H28N2O.ClH
Molecular Weight 312.878
Optical Activity ( + )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETIDOCAINE HYDROCHLORIDE, (+)-

SMILES

Cl.CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C

InChI

InChIKey=LMWQQUMMGGIGJQ-UHFFFAOYSA-N
InChI=1S/C17H28N2O.ClH/c1-6-12-19(8-3)15(7-2)17(20)18-16-13(4)10-9-11-14(16)5;/h9-11,15H,6-8,12H2,1-5H3,(H,18,20);1H

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://www.kiessig.com/drugs/druginfo.aspx?id=1218 | http://www.kiessig.com/drugs/druginfo.aspx?id=1218 | https://www.ncbi.nlm.nih.gov/pubmed/8799190 | https://www.ncbi.nlm.nih.gov/pubmed/8085162

Etidocaine, marketed under the trade name Duranest, is a local anesthetic given by injection during surgical procedures and labor and delivery. Etidocaine has a long duration of activity, and the main disadvantage of using during dentistry is increased bleeding during surgery. Etidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.

CNS Activity

Curator's Comment: http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2163529&blobtype=pdf

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DURANEST

Approved Use

INDICATIONS AND USAGE. Duranest (Etidocaine HCl) Injections are indicated for infiltration anesthesia, peripheral nerve blocks (e.g., brachial plexus, intercostal, retrobulbar, ulnar, inferior alveolar), and central neural block (i.e., lumbar or caudal epidural blocks).

Launch Date

1976
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
12.5 μg/mL
20 mL single, peridural
dose: 20 mL
route of administration: Peridural
experiment type: SINGLE
co-administered: EPINEPHRINE
ETIDOCAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.8 μg × h/mL
20 mL single, peridural
dose: 20 mL
route of administration: Peridural
experiment type: SINGLE
co-administered: EPINEPHRINE
ETIDOCAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.7 h
20 mL single, peridural
dose: 20 mL
route of administration: Peridural
experiment type: SINGLE
co-administered: EPINEPHRINE
ETIDOCAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
6%
20 mL single, peridural
dose: 20 mL
route of administration: Peridural
experiment type: SINGLE
co-administered: EPINEPHRINE
ETIDOCAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Relation of etidocaine and bupivacaine toxicity to rate of infusion in rhesus monkeys.
1977 Feb
Central-nervous-system toxicity of local anesthetic mixtures in monkeys.
1977 Mar
Alterations in the pharmacokinetic properties of amide local anaesthetics following local anaesthetic induced convulsions.
1988 Oct
Local anesthetic-induced toxicity may be modified by low doses of flumazenil.
1992
Relative neural toxicity of local anesthetics.
1993 May
Pain of injection and duration of anesthesia for intradermal infiltration of lidocaine, bupivacaine, and etidocaine.
1994 Jul
Molecular determinants of state-dependent block of Na+ channels by local anesthetics.
1994 Sep 16
Benefit and risks of local anesthetics in infants and children.
2002
Low-molecular-weight chiral cation exchangers: novel chiral stationary phases and their application for enantioseparation of chiral bases by nonaqueous capillary electrochromatography.
2002 Feb
Spectrophotometric determination of etidocaine in pharmaceutical (dental) formulation.
2002 Jul 20
Cardiac toxicity of local anesthetics in the intact isolated heart model: a review.
2002 Nov-Dec
Peribulbar anaesthesia using a combination of lidocaine, bupivocaine and clonidine in vitreoretinal surgery.
2002 Sep
Block of voltage-operated sodium channels by 2,6-dimethylphenol, a structural analogue of lidocaine's aromatic tail.
2002 Sep
Toxicity of local anaesthetics.
2003 Mar
Differential effects of uncharged aminoamide local anesthetics on phospholipid bilayers, as monitored by 1H-NMR measurements.
2005 May 1
Lipid rescue resuscitation from local anaesthetic cardiac toxicity.
2006
[Retrobulbar anesthesia during keratolplasty].
2006 Feb
Update on local anesthetics: focus on levobupivacaine.
2008 Apr
Cyclic metabolites: chemical and biological considerations.
2008 Feb
Preferential location of lidocaine and etidocaine in lecithin bilayers as determined by EPR, fluorescence and 2H NMR.
2008 Jan
Single injection peribulbar anesthesia with a short needle combined with digital compression.
2008 Nov
Advances in labor analgesia.
2010 Aug 9
Cardiogenic shock associated with loco-regional anesthesia rescued with left ventricular assist device implantation.
2010 Dec 8
The efficacy of ilioinguinal and iliohypogastric nerve block for postoperative pain after caesarean section.
2010 Jan
Intravenous lipid emulsion in clinical toxicology.
2010 Oct 5
Anesthesia for cataract surgery: Recent trends.
2010 Sep
Circadian effects on neural blockade of intrathecal hyperbaric bupivacaine.
2010 Sep
Patents

Patents

Sample Use Guides

The maximum dose to be employed as a single injection should be determined on the basis of the status of the patient and the type of regional anesthetic technique to be performed. Although single injections of 450 mg have been employed for regional anesthesia without adverse effects, at present it is strongly recommended that the maximal dose as a single injection should not exceed 400 mg (approximately 8.0 mg/kg or 3.6 mg/lb based on a 50 kg person) with epinephrine 1:200,000 and 300 mg (approximately 6 mg/kg or 2.7 mg/lb based on a 50 kg person) without epinephrine.
Route of Administration: Intramuscular
In Vitro Use Guide
Rat brain type IIA Na+ channels expressed in Xenopus oocytes were stimulated infrequently (1 pulse per 20 s, all currents were elicited by 15-ms pulses to 0 mV.) This tonic block mainly reflects drug binding to resting channels, the channel state that predominated at the holding potential of -90 mV. Etidocaine (200 mkM) decrease activities of WT Type IIA Na+ channels on ~40%.
Name Type Language
ETIDOCAINE HYDROCHLORIDE, (+)-
Common Name English
BUTANAMIDE, N-(2,6-DIMETHYLPHENYL)-2-(ETHYLPROPYLAMINO)-, MONOHYDROCHLORIDE, (+)-
Systematic Name English
Code System Code Type Description
FDA UNII
60YD32QL30
Created by admin on Sat Dec 16 11:18:36 GMT 2023 , Edited by admin on Sat Dec 16 11:18:36 GMT 2023
PRIMARY
PUBCHEM
37498
Created by admin on Sat Dec 16 11:18:36 GMT 2023 , Edited by admin on Sat Dec 16 11:18:36 GMT 2023
PRIMARY
CAS
38188-13-5
Created by admin on Sat Dec 16 11:18:36 GMT 2023 , Edited by admin on Sat Dec 16 11:18:36 GMT 2023
PRIMARY